At the previous close, the Oncology Pharma Inc. (OTCPINK: ONPH) share price rose noticeably, rising 93.40% to $37.00. Compared to the gain of 37.29% in the previous month, Oncology Pharma stock gained 45.38% over the last week. Recent news of an agreement pertaining to mRNA intellectual property (IP) triggered a surge of ONPH stock.
What is that IP deal all about?
Currently, Oncology Pharma is partnering with world-class advisory boards for oncology research and development. With these characteristics, ONPH is able to maintain a leading position when it comes to cancer research, healthcare, and biotechnology.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Oncology Pharma last week agreed to develop a therapeutic using mRNA for pancreatic cancer under a license agreement with Regen BioPharma Inc.
- ONPH plans to utilize this licensing agreement to expand its niche biotechnology intellectual property portfolio.
- In a statement, ONPH said that it intended to increase its presence in the cancer therapy market.
- The ONPH commitment to developing quality therapies to make patients lives better is exemplified by this effort.
- A spokesperson for ONPH said at the time the ONPH views this as a significant achievement in brand development and is evidence of it achieving its annual marketing goals.
Earlier updates:
Earlier in the previous month, Oncology Pharma (ONPH) unveiled its plans to develop and grow its business model and intellectual property. ONPH’s focus points include expanding its cancer therapies through the acquisition of licenses, formation of synergistic partnerships, and development of other niche therapies.
Additionally, ONPH’s strategic planning includes the goal of establishing financial partnerships that will enable licensed therapeutic agents to be developed. And the ONPH is heading in the right direction, as evidenced by the current developments.
